Rs2686344 and serum squamous cell carcinoma antigen could predict clinical efficacy of neoadjuvant chemotherapy for cervical cancer

T, Li; Huang, Huan; Hu, Yi; Chen, Hongwei; Li, Rui; Hao, Lu; Yan, Lin; Chen, Ying; Zhang, Chun; Zhang, Qinghua; Xiong, Li

doi:10.1016/j.currproblcancer.2021.100755

Cited by 7 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 6 Related studies have shown that NSE and SCC in serum can predict the effect of chemotherapy in patients with lung cancer. 7 , 8 However, there is still a lack of relevant research on the changes and clinical significance of NSE and SCC in serum in patients with lung cancer before and after radiotherapy. Therefore, the levels of NSE and SCC in serum in patients with lung cancer before and after radiotherapy were monitored and their clinical significance was discussed in this study.…”

Section: Introductionmentioning

confidence: 99%

Expression changes and clinical significance of serum neuron-specific enolase and squamous cell carcinoma antigen in lung cancer patients after radiotherapy

Sun¹,

Shao²

2023

Clinics

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Expression changes and clinical significance of serum neuron-specific enolase and squamous cell carcinoma antigen in lung cancer patients after radiotherapy

Sun¹,

Shao²

2023

Clinics

View full text Add to dashboard Cite

“…After a course of NACT and surgical specimens are taken after surgery, there is a certain risk of delaying treatment in this process 13 . Serum tumor markers are one of the most used clinical methods for evaluating specific treatment response, but they are insufficient in judging parametrial invasion and lymph node metastasis, and further diagnosis should be combined with imaging examinations 14 . Imaging examination has the advantages of noninvasive, fast, and convenient, and are more acceptable to both doctors and patients in the clinic 15,16 …”

Section: Introductionmentioning

confidence: 99%

“…13 Serum tumor markers are one of the most used clinical methods for evaluating specific treatment response, but they are insufficient in judging parametrial invasion and lymph node metastasis, and further diagnosis should be combined with imaging examinations. 14 Imaging examination has the advantages of noninvasive, fast, and convenient, and are more acceptable to both doctors and patients in the clinic. 15,16 Patients with CC can undergo ultrasound, magnetic resonance imaging (MRI), or CT scans before and after treatment to evaluate the short-term clinical effectiveness of NACT by comparing changes in tumor size with chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

An MRI‐based machine learning radiomics can predict short‐term response to neoadjuvant chemotherapy in patients with cervical squamous cell carcinoma: A multicenter study

Xin,

Yan,

Feng

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Background and PurposeNeoadjuvant chemotherapy (NACT) has become an essential component of the comprehensive treatment of cervical squamous cell carcinoma (CSCC). However, not all patients respond to chemotherapy due to individual differences in sensitivity and tolerance to chemotherapy drugs. Therefore, accurately predicting the sensitivity of CSCC patients to NACT was vital for individual chemotherapy. This study aims to construct a machine learning radiomics model based on magnetic resonance imaging (MRI) to assess its efficacy in predicting NACT susceptibility among CSCC patients.MethodsThis study included 234 patients with CSCC from two hospitals, who were divided into a training set (n = 180), a testing set (n = 20), and an external validation set (n = 34). Manual radiomic features were extracted from transverse section MRI images, and feature selection was performed using the recursive feature elimination (RFE) method. A prediction model was then generated using three machine learning algorithms, namely logistic regression, random forest, and support vector machines (SVM), for predicting NACT susceptibility. The model's performance was assessed based on the area under the receiver operating characteristic curve (AUC), accuracy, and sensitivity.ResultsThe SVM approach achieves the highest scores on both the testing set and the external validation set. In the testing set and external validation set, the AUC of the model was 0.88 and 0.764, and the accuracy was 0.90 and 0.853, the sensitivity was 0.93 and 0.962, respectively.ConclusionsMachine learning radiomics models based on MRI images have achieved satisfactory performance in predicting the sensitivity of NACT in CSCC patients with high accuracy and robustness, which has great significance for the treatment and personalized medicine of CSCC patients.

show abstract

“…Серологический опухолеассоциированный маркер SCCA (squamous cell carcinoma antigen) в течение многих лет используется при плоскоклеточном раке шейки матки (РШМ) для прогнозирования течения опухолевого процесса, мониторинга эффективности химио-и химиолучевой терапии, а также для доклинического выявления рецидивов заболевания в мониторинге больных после завершения первичного лечения [1][2][3][4][5][6][7][8]. В последние годы опубликован ряд статей, в которых исследуют возможность использования SCCA в качестве предиктора эффективности внутривенной неоадъювантной химиотерапии (НАХТ) по исходному уровню маркера и степени его снижения после 1-го курса химиотерапии.…”

Section: Introductionunclassified

Dynamics of level of the tumor-associated marker SCCA in neoadjuvant superselective intra-arterial chemotherapy in patients with cervical squamous cell carcinoma

Сергеева

Маршутина

Maltsagova

et al. 2023

Opuholi ženskoj reproduktivnoj sistemy

View full text Add to dashboard Cite

Background. Evaluation of a tumor-associated marker SCCA (squamous cell carcinoma antigen) level is used in cervical squamous cell carcinoma (CC) to predict the course of the tumor process, monitor the effectiveness of chemo- and chemoradiotherapy, and for preclinical detection of recurrence in follow-up of patients after the completion of primary treatment. However, publications devoted to the study of the possibility of using SCCA level as an additional criterion for the effectiveness of neoadjuvant intra-arterial chemotherapy (IACT) are still rare.Aim. Study of the tumor marker SCCA level in patients with locally advanced squamous CC during neoadjuvant IACT as an additional factor in assessing its effectiveness.Materials and methods. 53 patients with locally advanced squamous CC IB—IVB stages (T1b-3bN0-1M0-1) were included to the study. The mean age of patients was 45.6 years (25-64 years). All patients underwent superselective neoadjuvant IACT with cisplatine (in combination with intravenous administration of docetaxel or paclitaxel). Serum SCCA levels in CC patients were assessed before the first and after the second course of neoadjuvant IACT compared to the clinical effect of treatment after two courses (RECIST 1.1 criteria).Results. SCCA level after 2 courses decreased in all patients with initially increased its level, while the proportion of SCCA-positive cases decreased from 71.7 to 26.4 %. When baseline SCCA values were normal, a complete response was achieved more often than with initially elevated levels (26.7 % vs 15.8 %), while distribution by tumor stages was similar in both subgroups. It has been established that if, after 2 courses of neoadjuvant IACT, SCCA levels exceeds 2.1 ng/ml and/or (for patients with initially increased SCCA value) it decreased by less than 60 % from the baseline, probability to achieve complete response after realization of effect of 2 courses of IACT was extremely small. Strong correlation (R = 0.829) between initial level of SCCA and degree of its decrease after 2 courses of IACT was discovered in the group of patients with complete response after the second course of IACT. It was getting lower in partial response group (R = 0.778) and stabilization group (R = 0.750).Conclusion. Dynamics of SCCA level after 2 courses of IACT in squamous CC patients can be used as additional criterion of the degree of treatment effectiveness.

show abstract

Rs2686344 and serum squamous cell carcinoma antigen could predict clinical efficacy of neoadjuvant chemotherapy for cervical cancer

Cited by 7 publications

References 24 publications

Expression changes and clinical significance of serum neuron-specific enolase and squamous cell carcinoma antigen in lung cancer patients after radiotherapy

Expression changes and clinical significance of serum neuron-specific enolase and squamous cell carcinoma antigen in lung cancer patients after radiotherapy

An MRI‐based machine learning radiomics can predict short‐term response to neoadjuvant chemotherapy in patients with cervical squamous cell carcinoma: A multicenter study

Dynamics of level of the tumor-associated marker SCCA in neoadjuvant superselective intra-arterial chemotherapy in patients with cervical squamous cell carcinoma

Contact Info

Product

Resources

About